Mineralys Therapeutics, INC Form 4 insider transactions

Chief Medical Officer David Malcom Rodman exercised stock options in Mineralys Therapeutics, Inc. on September 11 and 12, 2024.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options at prices of $0.54 and $1.08 on August 12, 2024, resulting in the acquisition of 11,365 shares of common stock.

Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, reported the disposition of 550,000 shares of common stock at a price of $13.05 on July 24, 2024.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Chief Medical Officer of Mineralys Therapeutics, David Malcom Rodman, reports exercising stock options at prices of $0.54 and $1.08, increasing his direct ownership of common stock.

Mineralys Therapeutics CFO Adam Levy sold 10,757 shares of common stock at a weighted-average price of $13.1444 per share under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics CEO Jon Congleton sold 15,746 shares of common stock on July 11, 2024, at a weighted-average price of $13.3415, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Mineralys Therapeutics CEO Jon Congleton executed multiple sales of common stock between June 17 and June 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Alexander M. Gold acquired 44,000 stock options in Mineralys Therapeutics, Inc. on June 13, 2024.

Mineralys Therapeutics CEO Jon Congleton sold a significant number of shares between June 12 and June 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mineralys Therapeutics CFO Adam Levy sold 96,815 shares of common stock at a weighted-average price of $12.9393 per share under a pre-arranged 10b5-1 trading plan.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options at prices of $0.54 and $1.08, acquiring 5,017 and 6,349 shares respectively.

RA Capital Management and related parties report the acquisition of a stock option award in Mineralys Therapeutics, Inc.

Director Derek DiRocco acquired 22,000 stock options in Mineralys Therapeutics, Inc. on May 22, 2024.

Director Glenn Sblendorio acquired 22,000 stock options in Mineralys Therapeutics, Inc. on May 22, 2024.

Directors and 10% owners of Mineralys Therapeutics, Inc. report acquisition of stock options.

Director Daphne Karydas reports acquisition of 22,000 stock options in Mineralys Therapeutics.

Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, acquired 22,000 stock options on May 22, 2024, vesting monthly starting June 22, 2024.

Director Olivier Litzka acquired 22,000 stock options in Mineralys Therapeutics, Inc. on May 22, 2024.

Chief Medical Officer David Malcom Rodman exercised stock options at Mineralys Therapeutics, increasing his direct ownership of common stock.

Chief Medical Officer David Malcom Rodman exercised stock options and sold a small number of Mineralys Therapeutics shares under a pre-arranged trading plan.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., reports exercising stock options at prices of $0.54 and $1.08, resulting in the acquisition of 11,366 shares of common stock.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., reports exercising stock options at prices of $0.54 and $1.08, increasing his direct ownership of common stock.